• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-A12B filed by Dynavax Technologies Corporation

    10/29/24 4:07:25 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DVAX alert in real time by email
    8-A12B 1 d898351d8a12b.htm 8-A12B 8-A12B

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    FORM 8-A

    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

    PURSUANT TO SECTION 12(b) OR (g) OF

    THE SECURITIES EXCHANGE ACT OF 1934

    DYNAVAX TECHNOLOGIES

    CORPORATION

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   33-0728374
    (State of Incorporation or Organization)  

    (I.R.S. Employer

    Identification no.)

    2100 Powell Street, Suite 720

    Emeryville, California

      94608
    (Address of principal executive offices)   (Zip code)

    Securities to be registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class to

    be so Registered

     

    Name of Each Exchange on Which
    Each Class is to be Registered

    Preferred Share Purchase Rights   The NASDAQ Stock Market LLC

    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box. ☒

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following. ☐

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

    Securities Act registration statement or Regulation A offering statement file number to which this form

    relates (if applicable):

    Not applicable.

    Securities to be registered pursuant to Section 12(g) of the Act:

    None

     

     


    Item 1.

    Description of Registrant’s Securities to be Registered.

    On October 28, 2024, the Board of Directors (the “Board”) of Dynavax Technologies Corporation (the “Company”), a Delaware corporation, declared a dividend of one preferred share purchase right (“Right”) for each outstanding share of common stock, par value $0.001 per share, of the Company, and adopted a stockholder rights plan, as set forth in the Rights Agreement, dated as of October 28, 2024 (the “Rights Agreement”), by and between the Company and Computershare Trust Company, N.A., as rights agent. The dividend is payable on November 8, 2024 to stockholders of record of the Company as of the close of business on November 8, 2024.

    Each Right will allow its holder to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share, for $52.00, once the Rights become exercisable.

    The Rights are in all respects subject to and governed by the provisions of the Rights Agreement, which is incorporated herein by reference. The description of the Rights is incorporated herein by reference to the description set forth under Items 1.01, 3.03 and 5.03 of the Company’s Current Report on Form 8-K filed on October 29, 2024 and is qualified in its entirety by reference to the full text of the Rights Agreement included as Exhibit 4.1 to such Current Report.

     

    Item 2.

    Exhibits.

     

    Exhibit
    No.

      

    Description

    3.1    Amended and Restated Certificate of Designation of Series A Junior Participating Preferred Stock of Dynavax Technologies Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed on October 29, 2024).
    4.1    Rights Agreement, dated as of October 28, 2024, by and between Dynavax Technologies Corporation and Computershare Trust Company, N.A., as rights agent, which includes the Amended and Restated Certificate of Designation of Rights, Preferences and Privileges of Series A Junior Participating Preferred Stock of Dynavax Technologies Corporation as Exhibit A (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed on October 29, 2024) and the form of Right Certificate as Exhibit B (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed on October 29, 2024).


    SIGNATURE

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: October 29, 2024    

    DYNAVAX TECHNOLOGIES CORPORATION

       

    By:

     

    /s/ Kelly MacDonald

         

    Kelly MacDonald

    Chief Financial Officer

    Get the next $DVAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVAX

    DatePrice TargetRatingAnalyst
    2/11/2025$15.00 → $12.00Neutral → Sell
    Goldman
    2/1/2024$20.00Neutral
    Goldman
    9/27/2022$22.00Mkt Outperform
    JMP Securities
    1/6/2022$38.00Buy
    Goldman
    12/29/2021$23.00 → $28.00Buy
    HC Wainwright & Co.
    8/31/2021$20.00 → $23.00Buy
    HC Wainwright & Co.
    8/6/2021$19.00Buy
    Goldman Sachs
    8/5/2021$16.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DVAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:  S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec

    2/4/26 6:15:00 PM ET
    $ADT
    $ARWR
    $CIEN
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline

    Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price onDecember 23, 2025 EMERYVILLE, Calif., Dec. 24, 2025 /PRNewswire/ -- Sanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (NASDAQ:DVAX), a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and a differentiated shingles vaccine candidate. The acquisition augments Sanofi's presence in adult immunization by bringing together Dynavax's vaccines with Sanofi's global scale, development capabilities and commercial reach.

    12/24/25 1:23:00 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax to Participate at the 8th Annual Evercore Healthcare Conference

    EMERYVILLE, Calif., Nov. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd at 2:10 p.m. ET. The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. About DynavaxDynavax is a

    11/19/25 4:01:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dynavax downgraded by Goldman with a new price target

    Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously

    2/11/25 7:05:05 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Dynavax with a new price target

    Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00

    2/1/24 6:20:13 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on Dynavax with a new price target

    JMP Securities initiated coverage of Dynavax with a rating of Mkt Outperform and set a new price target of $22.00

    9/27/22 7:39:04 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Emini Emilio returned 10,075 units of Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    2/10/26 4:15:20 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Myers Scott Dunseth returned 31,204 units of Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    2/10/26 4:15:20 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VP, Chief Accounting Officer Metzinger Joseph Anthony closing all direct ownership in the company (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    2/10/26 4:15:25 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Myers Scott Dunseth bought $41,116 worth of shares (3,800 units at $10.82), increasing direct ownership by 12% to 35,004 units (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    8/25/25 8:50:44 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    SEC Filings

    View All

    SEC Form S-8 POS filed by Dynavax Technologies Corporation

    S-8 POS - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

    2/10/26 4:26:50 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Dynavax Technologies Corporation

    S-8 POS - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

    2/10/26 4:25:59 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Dynavax Technologies Corporation

    S-8 POS - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

    2/10/26 4:24:39 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Leadership Updates

    Live Leadership Updates

    View All

    Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:  S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec

    2/4/26 6:15:00 PM ET
    $ADT
    $ARWR
    $CIEN
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deep Track Capital Comments on ISS Recommendation

    Strongly Disagrees with Recommendation and Believes ISS Ignored Key Issues in Its Incomplete Analysis ISS Has Chosen Not to Hold the Board Accountable for Its Underperformance in Recent Years, Heplisav's Waning Market Share Growth and Poor Corporate Governance Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.82% of the Company's outstanding shares, today issued the following statement in response to a report issued by Instit

    5/23/25 6:12:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

    ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleading Supplemental Materials Urges Stockholders to Follow ISS Recommendation and Vote "FOR" ALL Four of Dynavax's Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., May 23, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that leading independent proxy advisory firm, Institutional Shareholder Services ("ISS

    5/23/25 1:44:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Financials

    Live finance-specific insights

    View All

    Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

    HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; reiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 millionBoard of Directors authorizes new $100 million share repurchase program Positive topline Phase 1/2 shingles vaccine trial data presented in late-breaker session at IDWeek Enters exclusive license agreement for Vaxart's novel oral COVID-19 vaccine program, expanding pipeline opportunitiesConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vacc

    11/5/25 4:01:00 PM ET
    $DVAX
    $VXRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025

    EMERYVILLE, Calif., Oct. 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Wednesday, November 5, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://in

    10/22/25 4:01:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax Reports Second Quarter 2025 Financial Results

    Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growthRefines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, from $305 to $325 millionTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in August 2025Completed dosing in Part 1 of Phase 1/2 trial of pandemic influenza adjuvant programConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Aug. 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update

    8/7/25 4:00:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Dynavax Technologies Corporation

    SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    11/14/24 12:18:08 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dynavax Technologies Corporation

    SC 13D/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    10/24/24 4:06:57 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dynavax Technologies Corporation

    SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    10/16/24 9:37:13 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care